US WorldMeds, LLC
http://www.usworldmeds.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From US WorldMeds, LLC
October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms
Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals
Tech Transfer Roundup: Erasca Calls On MD Anderson To Advance Its RAS/MAPK Pipeline
Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.
Finance Watch: Venture Capital Dominates Biopharma Funding So Far In 2022
Private Company Edition: Biomedtracker found that 53% of financings during the first quarter were venture capital deals versus 32% in Q1 of last year. Also, Qiming closed a $260m fund, Transition Bio raised a $50m series A round, ProfoundBio completed a $70m series A+ and MycoMedica raised $60m.
ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates
ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Sloan Pharma S.a.r.l
- Solstice Neurosciences